Oliver is the Head of Strategy for Precision Medicine and Genomics at AstraZeneca (AZ). He is responsible for leading the development of companion diagnostics for AZ’s targeted therapies across oncology, respiratory, and cardiovascular therapy areas and helped to build AZ’s population genomics capability. He is also leading AZ’s preparedness for Brexit.
Prior to his current role, Oliver led AstraZeneca’s global antibiotics business and managed its $1.6bn sale to Pfizer. He has held senior positions in Corporate and Commercial Strategy and was the Country President in Southeast Asia. Previously, Oliver has worked in big pharma for Novartis and GSK, in government at the UK Prime Minister’s office, and was a strategy consultant at McKinsey & Co.
Oliver has a BA and MA in mathematics from Oxford University and an MBA from Harvard Business School. He is currently completing an MSc in Cancer & Therapeutics at Barts Cancer Institute/Queen Mary University of London with a focus on the application of advanced analytics/machine learning to large genomics datasets.